Valerio Therapeutics Société anonyme (EPA:ALVIO)

Market Cap	59.88M +472.0%
Revenue (ttm)	1.83M -3.1%
Net Income	-13.18M
EPS	-0.09
Shares Out	488.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,187
Average Volume	189,608
Open	0.1160
Previous Close	0.1210
Day's Range	0.1160 - 0.1225
52-Week Range	0.0422 - 0.3100
Beta	1.62
RSI	46.27
Earnings Date	Apr 2, 2026

About EPA:ALVIO

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; and PlatON, generates DecoyTAC combining DNA decoy molecules capable of cell penetration with a linker+E3 ligand. It also develops V-body platform, a bis...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 25
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALVIO

Financial Performance

In 2024, EPA:ALVIO's revenue was 1.79 million, a decrease of -0.39% compared to the previous year's 1.80 million. Losses were -23.93 million, 17.6% more than in 2023.